Peginterferon alfa-2a(Rhein-Minapharm)(Peginterferon alfa-2a(Rhein-Minapharm)) - 药物靶点：IFNAR_在研适应症：丙型肝炎_专利_临床

概要

基本信息

药物类型

干扰素、生物类似药

别名

Hansenula-derived peginterferon alpha-2a (Rhein-Minapharm)、PEG-IFN alpha-2a (Rhein-Minapharm)、PEG-interferon alpha-2a (Rhein-Minapharm)

+ [3]

靶点

IFNAR

作用方式

激动剂

作用机制

IFNAR激动剂(干扰素α/β受体复合体激动剂)

治疗领域

感染消化系统疾病

在研适应症

丙型肝炎

非在研适应症-

原研机构

Rhein-Minapharm

在研机构

Rhein-Minapharm

非在研机构-

最高研发阶段批准上市

首次获批日期

埃及 (2015-01-01),

丙型肝炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 32821

当前序列信息引自: *****

关联

29

项与 Peginterferon alfa-2a(Rhein-Minapharm) 相关的临床试验

JPRN-UMIN000015633

/ RecruitingN/AIIT

Assessment of efficacy and safety of PEG-IFN alpha-2a administration into patients with chronic hepatitis B on nuleoside analogue - Usefulness of PEG-IFN alpha-2a treatment in combination with nucleoside analogue

开始日期2014-11-10

申办/合作机构-

JPRN-UMIN000012937

/ RecruitingN/AIIT

Efficacy and safety of Simeprevir/PEG alpha-IFN-2a/RBV therapy for patients with chronic hepatitis C after resection of hepatocellular carcinoma - Simeprevir/PEG alpha-IFN-2a/RBV therapy for patients with chronic hepatitisC after resection of HCC

开始日期2014-03-10

申办/合作机构

Kansai Medical University

JPRN-UMIN000020124

/ RecruitingN/AIIT

Efficacy of preceding administration of Entecavir with PEG-IFN-alfa2a for patients with chronic hepatitis B, positive with HBe antigen in young aged populations - Efficacy of preceding administration of Entecavir with PEG-IFN-alfa2a for patients with chronic hepatitis B, positive with HBe antigen in young aged populations

开始日期2014-03-01

申办/合作机构-

100 项与 Peginterferon alfa-2a(Rhein-Minapharm) 相关的临床结果

登录后查看更多信息

100 项与 Peginterferon alfa-2a(Rhein-Minapharm) 相关的转化医学

登录后查看更多信息

100 项与 Peginterferon alfa-2a(Rhein-Minapharm) 相关的专利（医药）

登录后查看更多信息

429

项与 Peginterferon alfa-2a(Rhein-Minapharm) 相关的文献（医药）

2025-04-01·Journal of Hepatology

Critical perspectives on the efficacy of PegIFN-α-2a: Beyond initial findings

Letter

作者: Yu, Ting ; Shan, Dan ; Chen, Dong ; Yang, Yu

2024-06-12·Euroasian journal of hepato-gastroenterology

Efficacy of Pegylated Interferon-alpha-2a in Chronic Hepatitis Delta: Experience from a Tertiary Care Hospital in Karachi

Article

作者: Butt, Nazish ; Hussain, Riaz ; Arisar, Fakhar A Qazi ; Usmani, Muhammad T ; Mughal, Saba

BackgroundChronic hepatitis D (CHD) along with chronic hepatitis B (CHB) is an important cause of morbidity and mortality in patients with cirrhosis. It is a potentially curable infection that has long awaited a good treatment option.ObjectiveTo ascertain the efficacy of pegylated interferon (PEG-IFN)-alpha-2a in patients suffering from CHD. A tertiary care hospital experience from Pakistan.Materials and methodsThe study included 207 CHD polymerase chain reaction (PCR)-positive patients treated with PEG-IFN-alpha-2a between July 2020 and October 2022. Virological response rate (PCR negative) at weeks 24 and 48 was the primary endpoint. Secondary outcomes included partial response (>2 log reduction in PCR) and treatment failure rate (<2 log reduction in PCR).ResultsA total of 187 patients started PEG-IFN therapy, and 148 patients completed the assigned 48 weeks of therapy. Patients' mean age was 25.7 years with 65% being males. The virological response rate was 40.5% at week 24 and 32.4% at week 48. The partial response rate was 24% at both weeks 24 and 48. The treatment failure rate was 36% at week 24 and 44% at week 48. Hemoglobin, white blood cell (WBC) count, and total bilirubin were found to be predictive of treatment response. Side effects led to treatment discontinuation among eighteen patients and one patient died due to hepatic failure.ConclusionTherapy with PEG-IFN-alpha-2a shows suboptimal outcomes in patients with CHD. There is a strong need for more effective alternate therapies for CHD patients.How to cite this articleButt N, Usmani MT, Hussain R, et al. Efficacy of Pegylated Interferon-alpha-2a in Chronic Hepatitis Delta: Experience from a Tertiary Care Hospital in Karachi. Euroasian J Hepato-Gastroenterol 2024;14(1):51-55.

2024-05-27·Ocular Immunology and Inflammation

Effectiveness of Pegylated Interferon Alpha-2a in Post-Uveitic Macular Edema Previously Responding to Non-Pegylated Interferon

Article

作者: Gozzi, F. ; Adani, C. ; Aldigeri, R. ; Cimino, L. ; De Simone, L. ; Bolletta, E. ; Mastrofilippo, V. ; Salvarani, C. ; Gentile, P.

PURPOSETo evaluate the efficacy of pegylated interferon (PEG-IFN) alpha-2a to treat post-uveitic relapsing macular edema (ME) after withdrawal of non-PEG IFN alpha-2a or 2b to maintain treatment efficacy.METHODSThis retrospective study investigated subjects with post-uveitic ME who received weekly subcutaneous PEG-IFN alpha-2a injections. Comparisons between baseline central macular thickness (CMT) and best-corrected visual acuity (BCVA) and those at all follow-up visits were made.RESULTSSix patients (nine eyes) were treated and followed up for six months. CMT (mean [standard deviation]) decreased from 375[117] to 283[39] μm after one month (p < 0.001), remaining significantly lower up to the final follow-up visit at six months (275[38] μm, p = 0.008), and BCVA (0.21[0.16] logMAR at baseline) showed an improvement of 0.12[0.11] logMAR (p = 0.026) at six months. Neither recurrences nor any serious adverse events were recorded.CONCLUSIONSPost-uveitic ME patients were effectively and safely treated with PEG-IFN alpha-2a.

100 项与 Peginterferon alfa-2a(Rhein-Minapharm) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02747	-	L03AB11	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
丙型肝炎	埃及	Rhein-Minapharm	2015-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCD2023	N/A	皮肤T细胞淋巴瘤	105	PEG IFN a-2a	(鏇艱蓋艱艱憲願繭顧繭) = 製積製艱築夢襯鑰範繭繭淵廠艱積願鹽選夢積 (鬱築鏇夢壓選鏇選窪繭 ) 更多	-	2023-07-08
IAS2015	N/A	HIV感染 \| 丙型肝炎	-	pegIFN-a 2a 180 mg/week	鹽鏇艱顧艱膚觸鏇醖衊(鏇衊顧餘顧鹹壓醖繭艱) = 製築壓糧襯蓋襯鑰鬱遞衊鏇築遞襯鹽鏇糧鏇範 (襯蓋衊蓋網壓鏇鏇餘廠 ) 更多	-	2015-01-01
				pegIFN-a 2a 360 mg/week	鹽鏇艱顧艱膚觸鏇醖衊(鏇衊顧餘顧鹹壓醖繭艱) = 觸鹹襯廠鑰遞築網繭糧衊鏇築遞襯鹽鏇糧鏇範 (襯蓋衊蓋網壓鏇鏇餘廠 ) 更多
ASN2010	N/A	慢性丙型肝炎	28	PEGIFN-alpha-2a + Ribavirin	鹹憲築構鑰構繭窪鹽鹹(衊鑰選艱製夢醖獵鬱憲) = Dose reductions of PEGIFN and ribavirin were required for hematological side effects 襯齋鑰淵顧鹽鑰積衊壓 (餘淵窪構鬱遞繭膚鑰襯 ) 更多	不佳	2010-11-16
IAS2010	N/A	HIV感染 \| 慢性丙型肝炎	-	peginterferon alpha-2a (CASE group)	觸鬱鹽獵淵鏇廠鑰鹽蓋(鏇鑰繭製選蓋簾醖鬱繭) = 17(46%) patients in CASE group and 15(45%) in CONTROL group experienced adverse events (AEs) (p=0.99) 繭艱憲範構繭憲窪積鬱 (糧夢觸顧襯積壓鹽鹽鬱 ) 更多	-	2010-01-01
				peginterferon alpha-2a (CONTROL group)
IAS2008	N/A	合并感染	105	PEG-INF alpha-2a	簾築餘選廠糧蓋積淵遞(窪繭構廠構醖憲齋簾壓) = 窪網遞鏇廠鏇遞願願願鏇糧糧獵餘鏇獵蓋獵範 (壓憲鏇鏇衊蓋鑰積齋繭 )	-	2008-01-01
				PEG-INF alpha-2b	簾築餘選廠糧蓋積淵遞(窪繭構廠構醖憲齋簾壓) = 築艱顧選積構觸範憲繭鏇糧糧獵餘鏇獵蓋獵範 (壓憲鏇鏇衊蓋鑰積齋繭 )